Holen Sie sich die Stockscreener-App
3.855
1.08%
0.035
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt MYGN?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$3.82
Offen:
$3.83
24-Stunden-Volumen:
663.80K
Relative Volume:
0.35
Marktkapitalisierung:
$364.10M
Einnahmen:
$829.00M
Nettoeinkommen (Verlust:
$-399.90M
KGV:
-0.8932
EPS:
-4.3159
Netto-Cashflow:
$-23.20M
1W Leistung:
+8.77%
1M Leistung:
-19.22%
6M Leistung:
-49.19%
1J Leistung:
-1.24%
1-Tages-Spanne:
$3.72
$3.88
1-Wochen-Bereich:
$3.535
$3.95
52-Wochen-Spanne:
$3.53
$8.59
Myriad Genetics Inc Stock (MYGN) Company Profile
Firmenname
Myriad Genetics Inc
Sektor
Branche
Telefon
801-584-3600
Adresse
322 NORTH 2200 WEST, SALT LAKE CITY, UT
Compare MYGN vs TMO, DHR, IDXX, WAT, A
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MYGN
Myriad Genetics Inc
|
3.855 | 360.79M | 829.00M | -399.90M | -23.20M | -4.3159 |
TMO
Thermo Fisher Scientific Inc
|
448.96 | 166.59B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
173.03 | 121.74B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
557.96 | 44.12B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
339.70 | 33.62B | 3.77B | 449.25M | 240.68M | 7.8556 |
A
Agilent Technologies Inc
|
115.52 | 32.49B | 7.07B | 1.29B | 993.00M | 4.5355 |
Myriad Genetics Inc Stock (MYGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-21 | Herabstufung | Scotiabank | Sector Outperform → Sector Perform |
| 2025-05-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2025-05-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-04-09 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-12 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2025-02-12 | Eingeleitet | Craig Hallum | Buy |
| 2024-12-10 | Eingeleitet | UBS | Neutral |
| 2024-12-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-09-19 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-06-27 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-03 | Fortgesetzt | Jefferies | Underperform |
| 2024-05-08 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-21 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-12-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-07-05 | Fortgesetzt | JP Morgan | Underweight |
| 2023-05-23 | Hochstufung | Goldman | Sell → Buy |
| 2023-01-18 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-10-06 | Eingeleitet | Stephens | Equal-Weight |
| 2021-10-15 | Fortgesetzt | Cowen | Market Perform |
| 2021-06-15 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-03 | Eingeleitet | Goldman | Sell |
| 2019-09-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2019-08-14 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-08-02 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2019-08-01 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2019-07-29 | Herabstufung | Needham | Strong Buy → Hold |
| 2019-07-09 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-03-12 | Bestätigt | Needham | Strong Buy |
| 2019-01-03 | Eingeleitet | Needham | Strong Buy |
| 2018-11-30 | Hochstufung | Goldman | Sell → Neutral |
| 2018-10-10 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-07-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2018-03-21 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-01-29 | Eingeleitet | Goldman | Sell |
| 2018-01-22 | Bestätigt | Barclays | Equal Weight |
| 2018-01-05 | Eingeleitet | BTIG Research | Buy |
| 2017-10-02 | Fortgesetzt | Leerink Partners | Mkt Perform |
| 2017-08-09 | Bestätigt | Barclays | Equal Weight |
| 2017-02-08 | Hochstufung | Ladenburg Thalmann | Sell → Neutral |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Sell |
| 2016-10-10 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
Alle ansehen
Myriad Genetics Inc Aktie (MYGN) Neueste Nachrichten
MYGN Technical Analysis & Stock Price Forecast - Intellectia AI
Myriad Genetics (MYGN) price target decreased by 11.49% to 6.35 - MSN
Myriad Genetics | 5/22/26 - ktnv.com
MindWalk Holdings Leads Our Trio Of Promising Penny Stocks - simplywall.st
Myriad Genetics executives to speak at SOPHiA GENETICS event, spotlighting industry partnerships - Traders Union
‘American Idol’ Star Speaks Out on Health Issues 17 Years After Show Appearance - Parade
Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN) - Yahoo Finance
Myriad Genetics in record sell-off after Q1 miss - MSN
Stocks With 20% Upside: Dollar Tree, Myriad Genetics, Antero Resources AnalysisNews and Statistics - IndexBox
Myriad Genetics, Inc. (NASDAQ:MYGN) Given Average Rating of "Hold" by Analysts - MarketBeat
Myriad Genetics, Inc. $MYGN Shares Acquired by Vanguard Group Inc. - MarketBeat
Jackie Tohn joins Myriad Genetics in campaign to expand hereditary cancer test awareness - Traders Union
Myriad Genetics, Inc.Common Stock (NQ: MYGN - FinancialContent
Myriad Genetics and actress Jackie Tohn promote hereditary cancer testing after her BRCA1 gene discovery. - Pluang
Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life - markets.businessinsider.com
Myriad Genetics Partners with Jackie Tohn to Promote Hereditary Cancer Testing Awareness - Quiver Quantitative
Insider Buying: Paul Bisaro Acquires Shares of Myriad Genetics I - GuruFocus
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions - Yahoo Finance
Myriad Genetics director Paul Bisaro buys $27,637 in stock By Investing.com - Investing.com Australia
Myriad Genetics director Paul Bisaro buys $27,637 in stock - Investing.com UK
Paul Bisaro (NASDAQ: MYGN) adds 7,500 Myriad Genetics shares - Stock Titan
Myriad Genetics Inc stock (US62855J1043): shares react to Q1 2025 results and updated 2025 guidance - AD HOC NEWS
Global Cervical Cancer Diagnostics Market to Exhibit Growth at a CAGR of ~5% by 2034 | DelveInsight - GlobeNewswire Inc.
Myriad Genetics expands access to MyChoice Test for prostate cancer patients in Japan - SelectScience
Myriad Genetics unveils ultra-sensitive MRD testing focus at Tokyo oncology summit - Traders Union
Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop - AD HOC NEWS
State Street (MYGN) reports 4.42M Myriad shares, 4.7% stake - Stock Titan
FirstGene Multiple Prenatal Screen launch drives engagement at ACOG2026, Myriad Genetics advances genetic care - Traders Union
Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock - Insider Monkey
Myriad Genetics, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:MYGN) 2026-05-08 - Seeking Alpha
Myriad Genetics, Inc. (MYGN) Stock Analysis: Evaluating a Promising 77.94% Upside Potential - DirectorsTalk Interviews
Hereditary Cancer Testing Market Will Generate Booming Growth - openPR.com
Myriad Genetics Is Maintained at Equal-Weight by Wells Fargo - Moomoo
Myriad Genetics Is Maintained at Hold by TD Cowen - Moomoo
Myriad Genetics to join two healthcare conferences in upcoming weeks - Traders Union
Myriad Genetics to join BofA meetings, Goldman webcast in June - Stock Titan
Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences - GlobeNewswire
Myriad Genetics, Inc. (NASDAQ:MYGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Myriad Genetics Bets on Growth Amid Profit Squeeze - TipRanks
Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns - Sahm
Myriad Genetics (MYGN) reports Q1 loss, misses revenue estimates - MSN
Myriad Genetics Q1 2026 earnings preview - MSN
Finanzdaten der Myriad Genetics Inc-Aktie (MYGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Myriad Genetics Inc-Aktie (MYGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Raha Samraat S. | President and CEO |
Mar 09 '26 |
Buy |
5.00 |
40,000 |
199,844 |
493,104 |
| Phanstiel S. Louise | Director |
Feb 26 '26 |
Buy |
4.80 |
50,407 |
242,105 |
233,951 |
| Phanstiel S. Louise | Director |
Feb 27 '26 |
Buy |
4.66 |
48,000 |
223,728 |
281,951 |
| Phanstiel S. Louise | Director |
Feb 25 '26 |
Buy |
4.74 |
6,100 |
28,890 |
183,544 |
0.23%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):